.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Accenture
Fuji
Harvard Business School
Farmers Insurance
Cipla
Colorcon
Cerilliant
Chinese Patent Office

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,936,590

« Back to Dashboard

Which drugs does patent 6,936,590 protect, and when does it expire?


Patent 6,936,590 protects BYDUREON PEN, XIGDUO XR, FARXIGA, and QTERN, and is included in four NDAs.

Summary for Patent: 6,936,590

Title: C-aryl glucoside SGLT2 inhibitors and method
Abstract:A method is provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of a compound of the formula ##STR1## alone or in combination with one or more other antidiabetic agent(s) or other therapeutic agent(s).
Inventor(s): Washburn; William N. (Titusville, NJ), Ellsworth; Bruce (Princeton, NJ), Meng; Wei (Pennington, NJ), Wu; Gang (Princeton, NJ), Sher; Philip M. (Plainsboro, NJ)
Assignee: Bristol Myers Squibb Company (Princeton, NJ)
Application Number:10/264,410
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca AbBYDUREON PENexenatide syntheticFOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS022200-002Feb 28, 2014RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbXIGDUO XRdapagliflozin propanediol; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205649-005Jul 28, 2017RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbXIGDUO XRdapagliflozin propanediol; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205649-002Oct 29, 2014RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbXIGDUO XRdapagliflozin propanediol; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205649-001Oct 29, 2014RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbXIGDUO XRdapagliflozin propanediol; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205649-004Oct 29, 2014RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbXIGDUO XRdapagliflozin propanediol; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205649-003Oct 29, 2014RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbFARXIGAdapagliflozin propanediolTABLET;ORAL202293-001Jan 8, 2014RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbFARXIGAdapagliflozin propanediolTABLET;ORAL202293-002Jan 8, 2014RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbQTERNdapagliflozin propanediol; saxagliptin hydrochlorideTABLET;ORAL209091-001Feb 27, 2017RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Healthtrust
Covington
Dow
Julphar
US Army
Colorcon
Express Scripts
Federal Trade Commission
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot